Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01178944 · ClinicalTrials.gov registry record · Phase 2
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
A Phase 2 study of Gastric Adenocarcinoma and Adenocarcinoma of the Gastroesophageal Junction, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 2
- Study locations
NCT01178944 is a Phase 2 study of Gastric Adenocarcinoma and Adenocarcinoma of the Gastroesophageal Junction that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 35 participants, below the 245-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT01178944, a Phase 2 study of Gastric Adenocarcinoma and Adenocarcinoma of the Gastroesophageal Junction, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies how well pralatrexate and oxaliplatin work in treating patients with esophageal, stomach, or gastroesophageal junction cancer that cannot be removed by surgery or has spread from the primary site (place where it started) to other places in the body. Pralatrexate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pralatrexate with oxaliplatin may be an effective treatment for esophageal, stomach, or gastroesophageal junction cancer.
Conditions Studied
Interventions
- DRUG Oxaliplatin
- OTHER Laboratory Biomarker Analysis
- DRUG Pralatrexate
Study Locations (2)
New York
- Roswell Park Cancer Institute - Buffalo
- Rochester General Hospital - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2010-09 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01178944
The ClinicalTrials.gov registry entry for NCT01178944 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (86% lower). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Gastric Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Oxaliplatin is the first listed.
NCT01178944 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01178944 about?
NCT01178944 is a clinical study titled "Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer". This phase II trial studies how well pralatrexate and oxaliplatin work in treating patients with esophageal, stomach, or gastroesophageal junction cancer that cannot be removed by surgery or has spread from the primary site (place where it started) to other places in the body. Pralatrexate may stop ...
What is the current status of trial NCT01178944?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2010-09. Estimated completion is 2015-11.
What conditions does trial NCT01178944 study?
This clinical trial studies the following conditions: Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Stage IIIB Gastric Cancer, Stage IIIB Esophageal Adenocarcinoma, Gastric Squamous Cell Carcinoma.
What interventions are being tested in trial NCT01178944?
The interventions under investigation include: Oxaliplatin (DRUG), Laboratory Biomarker Analysis (OTHER), Pralatrexate (DRUG).
Who is sponsoring clinical trial NCT01178944?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01178944 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
RECRUITING · Phase 2
-
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
RECRUITING · Phase 2
-
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
RECRUITING · Phase 2
-
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
RECRUITING · Phase 2
-
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Gastric Adenocarcinoma
All registered trials for this condition
Adenocarcinoma of the Gastroesophageal Junction
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.